Study of Sonographic Efficacy of Rituximab in Rheumatoid Arthritis

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01765374

Acronym

SEWORRA

Enrollment

Registered

2013-01-10

Start date

2011-02-01

Completion date

2014-10-01

Last updated

2026-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

rituximab, sonography, clinical response

Brief summary

To detect by sonography relapse of disease activity prior to clinical symptoms in RA patients treated by rituximab.

Interventions

DEVICEESAOTE MyLab60

US evaluation at different time points

DRUGRituximab

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* failure to at least one TNF-blocking agent

Exclusion criteria

* pregnant or childbearing woman * Rituximab contraindication * woman unable to use contraceptive means

Design outcomes

Primary

Measure	Time frame	Description
global score of power-doppler activity measured by ultrasonography on 12 joints	at 6 months after initiation of rituximab and then every 2 month over the follow-up period (18 months)	Each time point will be assessed since the main objective of the study is to detect the time of sonographic relapse prior to clinical relapse

Countries

France

Contacts

PRINCIPAL_INVESTIGATOROlivier Vittecoq, MD,PHD

University Hospital, Rouen

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 17, 2026